Loading clinical trials...

Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors | Clinical Trials | Clareo Health

RECRUITINGNA

Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors

NCT06732375•Duke University

Summary

The purpose of this study is to evaluate the feasibility and acceptability of the Mindset Moments™ (MM™) program in managing psychological distress and resiliency in adolescent and young adult cancer survivors. Study participation will involve attending 8 weekly, one hour, live online group sessions and completing daily 5 minute activities such as guided imageries and CBT check in within the app. Participants will also be asked to complete an online survey at the time of enrollment and at 4 and 8 weeks.

Eligibility

Age

19 - 25 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•19-25 years of age
•Prior AYA cancer diagnosis
•Completed primary treatment for their cancer
•Score of 3 or above on the Distress Thermometer at the time of recruitment

Exclusion Criteria

•Individuals without legal capacity to give consent
•Individuals who are not fluent in reading, writing, and speaking English

Locations (1)

Duke Cancer Institute

Durham, North Carolina, United States

Key Dates

Start Date

June 13, 2025

Primary Completion Date

April 1, 2026

Completion Date

September 1, 2026

Last Updated

December 3, 2025

Enrollment

ESTIMATED participants

Conditions

CancerYouth CancerYoung Adult CancerDistress, Psychological

Interventions

Mindset Moments

BEHAVIORAL

Contacts

Andrea Pires, MS

CONTACT

919-660-8218 andrea.pires@duke.edu

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

RECRUITINGPHASE1/PHASE2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device